Practice Essentials

Monitoring and Managing Adverse Events in Older Adults with MDS
Monitoring and Managing Adverse Events in Older Adults with MDS
CME, CPE
Steven D. Gore, MD
Release Date: May 31, 2017
Expiration Date: May 31, 2018

Treatment selection is critical in older patients with myelodysplastic syndromes (MDS) who have an increased risk for experiencing treatment-emergent adverse events (TEAEs) and require tailored monitoring parameters and strategies for managing associated toxicities. In this activity, Dr. Gore will address the efficacy data of currently available therapies that must be considered in the selection of therapeutic regimens, as well as the major adverse events associated with each, and toxicities of notable concern in older patients with MDS. Managing TEAEs in older patients with significant comorbidities may reduce the potential for premature discontinuation of an otherwise effective therapy, allowing the patient maximum treatment benefit.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
Myelodysplastic Syndromes: Diagnosis, Classification, and Risk Stratification
Myelodysplastic Syndromes: Diagnosis, Classification, and Risk Stratification
CME, CPE
Rami S. Komrokji, MD
Release Date: April 27, 2017
Expiration Date: April 27, 2018

Accurate diagnosis is critical in myelodysplastic syndromes (MDS), and new criteria and guidelines are refining how MDS is diagnosed and assessed. This focused activity will include practice recommendations for using the revised diagnostic criteria and for improving the accuracy of assessments in patients who present with cytopenias and may have MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
The Evolving Treatment Landscape for High-Risk MDS
The Evolving Treatment Landscape for High-Risk MDS
CME, CPE
Bart Scott, MD
Release Date: December 16, 2016
Expiration Date: December 16, 2017

Risk-stratification of patients with myelodysplastic syndromes (MDS) is essential to appropriate treatment selection and optimization of patient outcomes. In this activity, Dr. Bart Scott will provide an overview of risk assessment tools to prognosticate patients and outline associated treatment options based on patient-specific factors. In addition, Dr. Scott will summarize new therapeutic options being investigated for the treatment of patients with high-risk MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
New and Emerging Strategies in the Treatment of High-Risk MDS Patients
New and Emerging Strategies in the Treatment of High-Risk MDS Patients
CME, CPE
David P. Steensma, MD, FACP
Release Date: November 16, 2016
Expiration Date: November 16, 2017

The treatment and management of patients with high-risk myelodysplastic syndromes (MDS) is challenging, owing in part to the complexities of risk-stratification, as well as limited available treatment options. In this activity, Dr. David Steensma, an Associate Professor of Medicine at Harvard Medical School, describes the appropriate identification of higher-risk MDS based on the revised International Prognostic Scoring System (IPSS-R) and recent data regarding the impact of cytogenetics on existing risk-stratification strategies. In addition, Dr. Steensma provides an overview of the treatment landscape in higher-risk MDS, including data to support existing treatment options and new therapies currently being investigated in clinical trials.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
The Changing Face of MDS: Advances in Prognosis and Diagnosis
The Changing Face of MDS: Advances in Prognosis and Diagnosis
CME, CPE
Guillermo Garcia-Manero, MD
Release Date: August 25, 2016
Expiration Date: August 25, 2017
The diagnosis and prognostication of disease can be very complex for patients with myelodysplastic syndromes (MDS). In this activity, Dr. Guillermo Garcia-Manero, Professor of Medicine and Chief of the Section of MDS at the MD Anderson Cancer Center (MDACC), will outline the challenges associated with diagnosing MDS, including discordance between referral and final diagnoses. He will also explain the utility of prognostic models, such as International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS) and the Global MDACC model, and ongoing research into the clinical significance of genetic mutations in MDS.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
The Changing Face of MDS: Advances in Treatment
The Changing Face of MDS: Advances in Treatment
CME, CPE
Guillermo Garcia-Manero, MD
Release Date: August 25, 2016
Expiration Date: August 25, 2017
The treatment algorithms for patients with myelodysplastic syndromes (MDS) have evolved into therapeutic strategies based on risk and prior therapy. In this activity, Dr. Guillermo Garcia-Manero, Professor of Medicine and Chief of the Section of MDS at the MD Anderson Cancer Center, will describe treatment options for high- and low-risk patients who are previously untreated or who have failed prior therapy with a hypomethylating agent. In addition, Dr. Garcia-Manero will provide clinical pearls for managing patients with MDS across the risk-spectrum to better personalize therapy and improve treatment outcomes.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Making Sure the Low Risk MDS Patient Remains Low Risk: Developing Effective Individualized Treatment Strategies
Making Sure the Low Risk MDS Patient Remains Low Risk: Developing Effective Individualized Treatment Strategies
CME, CPE
B. Douglas Smith, MD
Release Date: April 26, 2016
Expiration Date: April 26, 2017
Many patients diagnosed with low-risk MDS eventually progress to higher-risk disease. Join Dr. Douglas Smith as he discusses individualizing therapy to minimize the development of higher-risk MDS. Through an analysis of options for patient-centered treatment in low-risk MDS patients, both with and without 5Q deletion, Dr. Smith reviews the current standard of care and therapeutic options available in practice today.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Maintaining Long-term Efficacy in the Elderly MDS Patient with a Poor Performance Status
Maintaining Long-term Efficacy in the Elderly MDS Patient with a Poor Performance Status
CME, CPE
Hetty Carraway, MD
Release Date: January 27, 2016
Expiration Date: January 27, 2017
Join MDS expert, Hetty Carraway, MD, of the Taussig Cancer Institute at the Cleveland Clinic in a highly pertinent discussion regarding approaches to maintaining the long-term efficacy of treatment in elderly MDS patients with poor performance status.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Practical Tools for Management of Myelodysplastic Syndromes
Practical Tools for Management of Myelodysplastic Syndromes
CME, CPE
Sandra Kurtin, RN, MS, AOCN®, ANP-C
Release Date: November 17, 2015
Expiration Date: November 17, 2016
Join world-leading MDS expert Sandra Kurtin, clinical assistant professor of medicine and nurse practitioner at the Arizona Cancer Center within the University of Arizona, in a discussion of the practical tools and strategies for clinical management of patients newly diagnosed with MDS today, including patient and family education throughout the disease continuum.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Prognostic Risk Systems for Therapeutic Decision Making in Myelodysplastic Syndromes
Prognostic Risk Systems for Therapeutic Decision Making in Myelodysplastic Syndromes
CME, CPE
Stuart Goldberg, MD, and Peter Greenberg, MD
Release Date: July 17, 2015
Expiration Date: July 17, 2016
Join world-leading Managing MDS team experts Stuart Goldberg, MD, associate clinical professor of medicine at the John Theurer Cancer Center in Hackensack, New Jersey, and Peter Greenberg, MD, professor of medicine (hematology), director of the Stanford MDS Center at the Stanford University Cancer Center, coordinator of the International Working Group for the Prognosis of MDS (IWG-PM), and chair of the NCCN Myelodysplastic Syndromes Practice Guidelines Panel, in a case-based discussion evaluating the prognostic features of individual MDS patients including the use of morphological classification, as well as various risk systems including one of those most widely used in the United States today, the Revised International Prognostic Scoring System (IPSS-R), to determine MDS patients’ risk category, associated prognosis, and recommended treatment strategies..

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Emerging Therapies and Clinical Trials: What’s on the Horizon?
Emerging Therapies and Clinical Trials: What’s on the Horizon?
CME, CPE
Stuart Goldberg, MD, and Azra Raza, MD
Release Date: May 12, 2015
Expiration Date: May 12, 2016

Join Stuart Goldberg, MD, and Azra Raza, MD, in a lively and frank practice-oriented discussion centered on two common real-world presentations of elderly MDS patients, one with low-risk disease and one with high-risk disease, and how they were evaluated and managed according to the most current clinical evidence for today’s approaches to disease management. Drs. Goldberg and Raza also explore what is new on the horizon for MDS management after each of these cases, including strategies that are undergoing clinical investigations to address outstanding clinical uncertainties and barriers to improved patient outcomes for low- and high-risk disease patients with a discussion of the trial results which either impact your practice today or have the potential to do so in the near future according to data that has been recently reported.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Prognosis and Treatment Planning for Myelodysplastic Syndromes
Prognosis and Treatment Planning for Myelodysplastic Syndromes
CME, CPE, CNE
Mikkael A. Sekeres, MD, MS, and Rafael Bejar, MD, PhD
Release Date: September 25, 2014
Expiration Date: September 25, 2015

Drs. Mikkael Sekeres and Rafael Bejar compare and contrast the different staging prognostic systems including the strengths and limitations of each system, discuss how genetic analysis, including next-generation sequencing may affect prognostic systems, and the impact on tailoring therapy for patients with myelodysplastic syndrome.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved